Certara, Inc. (NASDAQ:CERT) Stock Rated “Hold” by Sell-Side Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have been given a consensus recommendation of “Hold” by the twelve research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $9.18.

CERT has been the topic of several research reports. TD Cowen lifted their target price on Certara from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. KeyCorp increased their price target on Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Weiss Ratings cut Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. UBS Group reaffirmed a “neutral” rating and issued a $10.00 price objective on shares of Certara in a research note on Wednesday, September 30th. Finally, Barclays upped their price objective on Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th.

Institutional Investors Weigh In On Certara

Large investors have recently bought and sold shares of the business. GAMMA Investing LLC increased its position in Certara by 21.2% in the third quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock worth $90,000 after purchasing an additional 1,710 shares during the last quarter. Sequoia Financial Advisors LLC lifted its position in Certara by 12.0% during the second quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock valued at $117,000 after purchasing an additional 1,923 shares during the last quarter. NorthRock Partners LLC bought a new position in Certara during the second quarter valued at $68,000. Integrated Wealth Concepts LLC bought a new stake in shares of Certara in the 2nd quarter worth about $39,000. Finally, Corient Private Wealth LP increased its holdings in shares of Certara by 166.8% in the 2nd quarter. Corient Private Wealth LP now owns 74,316 shares of the company’s stock worth $487,000 after buying an additional 46,462 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

CERT opened at $10.61 on Tuesday. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -23.58 and a beta of 1.42. The company has a fifty day moving average of $8.78 and a 200 day moving average of $7.26. Certara has a fifty-two week low of $4.45 and a fifty-two week high of $12.94. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The company had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business’s revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.07 earnings per share. As a group, sell-side analysts forecast that Certara will post 0.22 earnings per share for the current fiscal year.

About Certara

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.